Clinical Assessment of Prostate Displacement and Planning Target Volume Margins for Stereotactic Body Radiotherapy of Prostate Cancer

Clinical Assessment of Prostate Displacement and Planning Target Volume Margins for Stereotactic Body Radiotherapy of Prostate Cancer

Purpose: To assess the optimal planning target volume (PTV) margins for stereotactic body radiotherapy (SBRT) of prostate cancer based on inter- and intra-fractional prostate motion determined from daily image guidance.Methods and Materials: Two hundred and five patients who were enrolled on two pro...

Full description

Bibliographic Details
Main Authors:	Rebecca Levin-Epstein, George Qiao-Guan, Jesus E. Juarez, Zhouhuizi Shen, Michael L. Steinberg, Dan Ruan, Luca Valle, Nicholas G. Nickols, Patrick A. Kupelian, Christopher R. King, Minsong Cao, Amar U. Kishan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-04-01
Series:	Frontiers in Oncology
Subjects:	prostate cancer stereotactic body radiation therapy SBRT prostate motion planning target volume margins
Online Access:	https://www.frontiersin.org/article/10.3389/fonc.2020.00539/full

Similar Items

Editorial: Stereotactic body radiotherapy for prostate cancer
by: Amar U. Kishan, et al.
Published: (2022-10-01)

Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial
by: Ting Martin Ma, et al.
Published: (2021-05-01)

Rectal Radiation Dose and Clinical Outcomes in Prostate Cancer Patients Treated With Stereotactic Body Radiation Therapy With and Without Hydrogel
by: Palak Kundu, et al.
Published: (2022-03-01)

Development and Validation of a Comprehensive Multivariate Dosimetric Model for Predicting Late Genitourinary Toxicity Following Prostate Cancer Stereotactic Body Radiotherapy
by: Luca F. Valle, et al.
Published: (2020-05-01)

Interfractional Geometric Variations and Dosimetric Benefits of Stereotactic MRI Guided Online Adaptive Radiotherapy (SMART) of Prostate Bed after Radical Prostatectomy: Post-Hoc Analysis of a Phase II Trial
by: Minsong Cao, et al.
Published: (2021-06-01)

Ablative Radiotherapy in Prostate Cancer: Stereotactic Body Radiotherapy and High Dose Rate Brachytherapy
by: Ting Martin Ma, et al.
Published: (2020-12-01)

Imaging Biomarkers in Prostate Stereotactic Body Radiotherapy: A Review and Clinical Trial Protocol
by: Wei Liu, et al.
Published: (2022-04-01)

Favorable Biochemical Freedom From Recurrence With Stereotactic Body Radiation Therapy for Intermediate and High-Risk Prostate Cancer: A Single Institutional Experience With Long-Term Follow-Up
by: Anthony Ricco, et al.
Published: (2020-09-01)

MRI-Guided Radiation Therapy for Prostate Cancer: The Next Frontier in Ultrahypofractionation
by: Cecil M. Benitez, et al.
Published: (2023-09-01)

Long-Term Outcomes of Stereotactic Body Radiotherapy (SBRT) for Intraprostatic Relapse after Definitive Radiotherapy for Prostate Cancer: Patterns of Failure and Association between Volume of Irradiation and Late Toxicity
by: Marcin Miszczyk, et al.
Published: (2023-02-01)

Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
by: Einsley-Marie eJanowski, et al.
Published: (2015-07-01)

Virtual HDR Boost for Prostate Cancer: Rebooting a Classic Treatment Using Modern Tech
by: Eric Wegener, et al.
Published: (2023-03-01)

Stereotactic focal radiotherapy as an alternative treatment for low-risk prostate cancer: Results of a single-arm monocenter Phase-II trial
by: Paul V. Nguyen, et al.
Published: (2023-04-01)

Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
by: Ju Andrew W, et al.
Published: (2013-01-01)

Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer
by: Abigail N. Pepin, et al.
Published: (2022-01-01)

Multi-institutional Registry for Prostate Cancer Radiosurgery: An Observational Clinical Trial
by: Debra eFreeman, et al.
Published: (2015-01-01)

Editorial: The Evolving Landscape of Stereotactic Body Radiation Therapy for the Management of Prostate Cancer
by: Seth R. Blacksburg, et al.
Published: (2020-12-01)

Focal Prostate Stereotactic Body Radiation Therapy With Correlative Pathological and Radiographic-Based Treatment Planning
by: Elisha Fredman, et al.
Published: (2021-09-01)

Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy
by: Michael Carrasquilla, et al.
Published: (2021-01-01)

The Early Result of Whole Pelvic Radiotherapy and Stereotactic Body Radiotherapy Boost for High Risk Localized Prostate Cancer
by: Yu-Wei eLin, et al.
Published: (2014-10-01)

A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT)
by: Sydney Wolfe, et al.
Published: (2023-09-01)

Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer
by: Sarthak Shah, et al.
Published: (2021-11-01)

Prognostic utility of biopsy-based PTEN and ERG status on biochemical progression and overall survival after SBRT for localized prostate cancer
by: Michael C. Repka, et al.
Published: (2024-03-01)

Association of baseline self-reported fatigue with overall survival after stereotactic body radiation therapy for localized prostate cancer
by: Rishabh K. Simhal, et al.
Published: (2022-12-01)

Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes
by: Michael Carrasquilla, et al.
Published: (2023-11-01)

CT-based online adaptive radiotherapy improves target coverage and organ at risk (OAR) avoidance in stereotactic body radiation therapy (SBRT) for prostate cancer
by: Michael Waters, et al.
Published: (2024-01-01)

Extreme Hypofractionation with SBRT in Localized Prostate Cancer
by: Maria Antonia Gómez-Aparicio, et al.
Published: (2021-08-01)

Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer
by: Charles C. Vu, et al.
Published: (2014-01-01)

Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease
by: Neil R. Parikh, et al.
Published: (2019-04-01)

Assessment of planning target volume margins in 1.5 T magnetic resonance‐guided stereotactic body radiation therapy for localized prostate cancer
by: Bin Yang, et al.
Published: (2022-06-01)

In regard to Cuccia et al.: impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy
by: Hamed Ghaffari, et al.
Published: (2020-08-01)

A Phase II Trial of SABR (Stereotactic Ablative Body Radiotherapy) for Low-Risk Prostate Cancer Using a Non-Robotic Linear Accelerator and Real-Time Target Tracking: Report of Toxicity, Quality of Life and Disease Control Outcomes with 5-Year Minimum Followup
by: Constantine Anastasios Mantz
Published: (2014-11-01)

Stereotactic Radiotherapy after Radical Prostatectomy in Patients with Prostate Cancer in the Adjuvant or Salvage Setting: A Systematic Review
by: Christina Schröder, et al.
Published: (2022-01-01)

Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP)
by: Abigail Pepin, et al.
Published: (2020-05-01)

Stereotactic Body Radiotherapy: Hitting Harder, Faster, and Smarter in High-Risk Prostate Cancer
by: Rohann J. M. Correa, et al.
Published: (2022-07-01)

Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer
by: Lindsey Gallagher, et al.
Published: (2023-10-01)

Oligometastatic Squamous Cell Transformation From Metastatic Prostate Adenocarcinoma Treated With Systemic and Focal Therapy: A Case Report
by: Karen Autio, et al.
Published: (2022-08-01)

Short-Term Outcomes and Clinical Efficacy of Stereotactic Body Radiation Therapy (SBRT) for Oligometastases of Prostate Cancer in China
by: Chenyang Xu, et al.
Published: (2022-04-01)

Large Prostate Volume Does Not Negatively Impact Health-Related Quality of Life in Patients with Prostate Cancer Treated with Ultrahypofractionated Stereotactic Body Radiotherapy
by: Piotr Milecki, et al.
Published: (2023-01-01)

Online adaptive planning for prostate stereotactic body radiotherapy using a 1.5 Tesla magnetic resonance imaging-guided linear accelerator
by: Jinzhong Yang, et al.
Published: (2021-01-01)